Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DeTACT Africa triple artemisinin combination therapies trial
PACTR202104845356660Phase 3Recruiting
- Sponsor
- University of Oxford
- Start
- Sep 2020
- Modality
- Small Molecules
- Countries
- 8
01
Overview
Phase 3 trial of artemether, lumefantrine, artesunate, mefloquine, amodiaquine and 1 more in Malaria (4 arms), sponsored by University of Oxford. Primary endpoint: 42-day efficacy defined as PCR-corrected adequate clinical and parasitological response. Started Sep 2020; status: recruiting.
02
Drugs
artemetherlumefantrineartesunatemefloquineamodiaquine
03
Conditions
Malaria
Beyond the preview
Go deeper on PACTR202104845356660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202104845356660.